Penumbra/$PEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Penumbra
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
Ticker
$PEN
Sector
Trading on
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
4,500
ISIN
US70975L1070
Website
Penumbra Metrics
BasicAdvanced
$9.9B
236.85
$1.08
0.53
-
Price and volume
Market cap
$9.9B
Beta
0.53
52-week high
$310.00
52-week low
$148.00
Average daily volume
602K
Financial strength
Current ratio
6.302
Quick ratio
3.447
Long term debt to equity
16.972
Total debt to equity
18.193
Interest coverage (TTM)
110.49%
Management effectiveness
Return on assets (TTM)
5.82%
Return on equity (TTM)
3.50%
Valuation
Price to earnings (TTM)
236.85
Price to revenue (TTM)
7.946
Price to book
8.14
Price to tangible book (TTM)
9.49
Price to free cash flow (TTM)
65.552
Growth
Revenue change (TTM)
13.17%
Earnings per share change (TTM)
-54.65%
3-year revenue growth (CAGR)
16.60%
3-year earnings per share growth (CAGR)
81.99%
What the Analysts think about Penumbra
Analyst ratings (Buy, Hold, Sell) for Penumbra stock.
Penumbra Financial Performance
Revenues and expenses
Penumbra Earnings Performance
Company profitability
Penumbra News
AllArticlesVideos
3 Mid-Cap Medical Stocks Outperforming the Market
MarketBeat·1 month ago
Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst
Benzinga·1 month ago
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Penumbra, Inc. (NYSE: PEN) and Encourages Current Penumbra Shareholders to Contact the Firm
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Penumbra stock?
Penumbra (PEN) has a market cap of $9.9B as of June 06, 2025.
What is the P/E ratio for Penumbra stock?
The price to earnings (P/E) ratio for Penumbra (PEN) stock is 236.85 as of June 06, 2025.
Does Penumbra stock pay dividends?
No, Penumbra (PEN) stock does not pay dividends to its shareholders as of June 06, 2025.
When is the next Penumbra dividend payment date?
Penumbra (PEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Penumbra?
Penumbra (PEN) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.